Pacific Biosciences of California, Inc.
PACB- Exchange
- Nasdaq
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001299130
In the last 90 days, Pacific Biosciences of California, Inc. insiders filed 0 open-market purchases and 1 sale; 223 institutions reported holding it in 13F filings for Q2 2026, worth $320.8M in total; superinvestors ARK Invest and HHLR Advisors (Hillhouse) hold it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Pacific Biosciences of California, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $30.4K in total
- Insiders trading
- 1
- Net value
- −$30.4K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Pacific Biosciences of California, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Van Oene Mark | See Remarks | 2,705,853 | Aug 18, 2026 | 5 |
| Milligan John F | Director | 132,821 | Jun 4, 2026 | 1 |
| Ordonez Kathy | Director | 403,037 | Jun 4, 2026 | 1 |
| Livingston Randall S | Director | 22,821 | Jun 4, 2026 | 1 |
| Mohr Marshall | Director | 132,821 | Jun 4, 2026 | 1 |
| Smith Christopher M | Director | 54,099 | Jun 4, 2026 | 1 |
| Ericson William W. | Director | 41,616 | Jun 4, 2026 | 1 |
| Valantine Hannah | Director | 22,821 | Jun 4, 2026 | 1 |
| Gibson Christopher | Director | 111,386 | Jun 4, 2026 | 3 |
| Gibson James R II | See Remarks | 1,245,663 | Apr 3, 2026 | 2 |
| Henry Christian O | See Remarks | 3,581,813 | Mar 4, 2026 | 3 |
| Farmer Michele | See Remarks | 305,948 | Mar 4, 2026 | 3 |
| Shapiro Lucy | Director | 22,821 | Jun 6, 2025 | 0 |
| Kim Susan G. | See Remarks | 695,654 | Oct 2, 2024 | 0 |
| Eidel Jeff | See Remarks | 869,730 | Aug 20, 2024 | 0 |
| Meline David W | Director | 57,116 | Jun 20, 2024 | 0 |
| Botstein David | Director | – | May 26, 2023 | 0 |
| Fromen Peter | See Remarks | 190,280 | Mar 4, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 3, 2022 (view filing) | Sep 29 | 4 days | Kim Susan G.See Remarks | SSale | −13.0K | $5.61 | −$72.8K | −7.3%163.5K after | |
| Sep 19, 2022 (view filing) | Sep 15 | 4 days | Henry Christian OSee Remarks | SSale | −91.3K | $5.78 | −$527.8K | −11.7%688.6K after | |
| May 20, 2022 (view filing) | May 18 | 2 days | Farmer MicheleSee Remarks | SSale | −3.57K | $5.55 | −$19.8K | −5.6%60.4K after | |
| Feb 22, 2022 (view filing) | Feb 17 | 5 days | Kim Susan G.Chief Financial Officer | SSale | −1.06K | $11.06 | −$11.7K | −0.8%135.0K after | |
| Feb 22, 2022 (view filing) | Feb 17 | 5 days | Henry Christian OPresident & CEO | SSaleCommons Stock | −2.12K | $11.09 | −$23.5K | −0.3%672.4K after | |
| Feb 17, 2022 (view filing) | Feb 16 | 1 day | Ordonez KathyDirector | SSale | −3.28K | $11.50 | −$37.7K | −15.0%18.6K after | |
| Jan 13, 2022 (view filing) | Jan 11 | 2 days | Van Oene MarkChief Operating Officer | SSale | −41.5K | $14.23 | −$590.3K | −12.4%293.5K after | |
| Jan 13, 2022 (view filing) | Jan 11 | 2 days | Fromen PeterChief Commercial Officer | SSale | −19.7K | $14.30 | −$282.0K | −12.3%140.3K after | |
| Oct 1, 2021 (view filing) | Sep 29 | 2 days | Kim Susan G.Chief Financial Officer | SSale | −20.3K | $25.75 | −$522.0K | −13.0%136.0K after | |
| Sep 20, 2021 (view filing) | Sep 16 | 4 days | Henry Christian OPresident & CEO | SSale | −90.5K | $26.91 | −$2.44M | −11.8%674.5K after | Amended |